US Patent

US8486456 — Itraconazole compositions with improved bioavailability

Method of Use · Assigned to Abbott GmbH and Co KG · Expires 2028-10-03 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a solid dispersion product containing itraconazole and hydroxypropyl methylcellulose with improved bioavailability.

USPTO Abstract

A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ÎH tr (1) (wherein ÎH tr represents the endotherm (J/g) accompanying a transition at about 240Â° C). The solid dispersion product shows an improved bioavailability.

Drugs covered by this patent

Sporanox (itraconazole) · Sebela Ireland Ltd

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1054`	—	Sporanox

Patent Metadata

Patent number: US8486456
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-03
Drug substance claim: No
Drug product claim: Yes
Assignee: Abbott GmbH and Co KG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.